P04439 (HLAA_HUMAN) Homo sapiens (Human)
HLA class I histocompatibility antigen, A alpha chain UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
384 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of HLA-A3*01 in complex with a mutant beta-catenin peptide |
Heteromer P35222; P61769; | 100 | 2×MES; 10×SO4; 2×PEG; | |||
| Crystal Structure of HLA A*0301 in complex with ILRGSVAHK, a 9-mer epitope from Influenza A |
Heteromer P26079; P61769; | 100 | 2×SO4; | |||
| Crystal structure of HLA-A3*01 in complex with a wild-type beta-catenin peptide |
Heteromer P35222; P61769; | 100 | 2×PG4; 3×MES; 2×IMD; 4×PEG; 7×EDO; | |||
| Crystal Structure of HLA-A*03:01 in complex with VVRPSVASK, an 9-mer epitope from Influenza B virus |
Heteromer P13884; P61769; | 100 | 3×SO4; | |||
| Structure of KRAS WT(7-16)-HLA-A*03:01 |
Heteromer P01116; P61769; | 100 | 13×SO4; 1×PEG; | |||
| Structure of KRAS G12V/HLA-A*03:01 in complex with antibody fragment V2 |
Heteromer P01116; P61769; | 100 | ||||
| HLA-A02 carrying YLGGPDFPTI |
Heteromer P61769; | 93.09 | 14×EDO; 1×SO4; | |||
| HLA-A02 carrying MVWGPDPLYV |
Heteromer P61769; | 93.09 | 10×EDO; 4×GOL; | |||
| CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX |
Heteromer P43358; P61769; | 93.09 | 2×1PG; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide A7H v… |
Heteromer P61769; Q6SW59; | 92.73 | ||||
| A structural basis for immunodominant human T-cell receptor recognition. |
Heteromer P01848; P01850; P61769; | 93.09 | ||||
| Crystal structure of HLA-A*1101 with sars nucleocapsid peptide |
Heteromer P59595; P61769; | 97.45 | 3×SO4; 7×GOL; | |||
| HLA-A02 carrying RQWGPDPAAV |
Heteromer P61769; | 93.09 | 18×EDO; 1×GOL; 1×MES; 4×SO4; 2×ACY; | |||
| HLA-A02 carrying YLGGPDFPTI |
Heteromer P61769; | 93.09 | 1×BR; 17×EDO; 4×GOL; 11×PG4; | |||
| Engineered Human HLA_A2 MHC Class I molecule in complex with NV9 peptide |
Heteromer P61769; | 92.0 | 2×GOL; 7×CO; | |||
| HAL-A02 carrying RQFGPDFPTI |
Heteromer P61769; | 93.09 | 10×EDO; 4×GOL; 2×SO4; 1×CA; | |||
| HLA Class I antigen |
Heteromer P40967; P61769; | 93.09 | 18×EDO; 10×GOL; 8×SO4; | |||
| Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A27L su… |
Heteromer P61769; Q16655; | 93.09 | 3×GOL; 3×FMT; 1×NA; | |||
| HLA A02 presenting SLYNTIATL |
Heteromer P04591; P61769; | 93.09 | 7×EDO; 5×GOL; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with Human Prostaglandin Transporter dec… |
Heteromer P61769; Q92959; | 92.73 | ||||
| The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its V… |
Heteromer P03485; P61769; | 93.09 | ||||
| Human Class I MHC HLA-A2 in complex with the HuD (G2L) peptide variant |
Heteromer P61769; | 93.09 | 3×GOL; | |||
| T cell cross-reactivity and conformational changes during TCR engagement. |
Heteromer P61769; | 93.09 | ||||
| T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT |
Heteromer P61769; | 93.09 | ||||
| Crystal Structure of HLA-A68 presenting a C-terminally extended peptide |
Heteromer P30279; P61769; | 94.18 | 6×EDO; 3×NI; 2×CD; 1×CO; | |||
| HLA-A2.1 KVAEIVHFL |
Heteromer E0YFW1; P61769; | 93.09 | ||||
| HLA-A02 carrying RQFGPDWIVA |
Heteromer P61769; | 93.09 | 11×EDO; 2×SO4; 1×CA; 1×GOL; | |||
| Structure of HLA-A2 in complex with an altered peptide ligands based on Mart-1 variant epitope |
Heteromer P61769; Q16655; | 93.09 | 4×GOL; | |||
| Ca2+ release from the endoplasmic reticulum of NY-ESO-1 specific T cells is modulated by the affini… |
Heteromer P61769; P78358; | 93.09 | ||||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P35222; P61769; | 93.09 | 6×CD; 2×MG; 2×GOL; | |||
| Human Class I MHC HLA-A2 in complex with the HuD peptide |
Heteromer P61769; | 93.09 | 5×GOL; | |||
| HLA A02 presenting SLFNTIAVL |
Heteromer P04591; P61769; | 93.09 | 9×EDO; 1×GOL; 2×SO4; | |||
| Human HLA-A*0201-ALWGPDPAAA |
Heteromer P01308; P61769; | 93.09 | ||||
| Human Class I MHC HLA-A2 in complex with Mart-1(27-35) nonameric peptide |
Heteromer P61769; Q16655; | 93.09 | 4×GOL; 1×NA; | |||
| HLA-A02 carrying AQWGPDPAAA |
Heteromer P01308; P61769; | 93.09 | ||||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P35222; P61769; | 93.09 | 3×GOL; 2×MG; 6×CD; | |||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; P61769; P78358; | 93.09 | ||||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P61769; Q9Y4H2; | 93.09 | 5×CD; 2×MG; 2×GOL; | |||
| Crystal Structure of RTY Phosphopeptide Bound to Human Class I MHC HLA-A2 |
Heteromer P61769; Q8WVV4; | 93.09 | 1×NA; 2×EDO; | |||
| Human Class I MHC HLA-A2 in complex with the nonameric Melan-A/MART-1(27-35) peptide having A28L su… |
Heteromer P61769; Q16655; | 93.09 | 4×GOL; 1×NA; | |||
| Structure of HLA-A2 P130 |
Heteromer P61769; Q76R61; | 93.09 | 1×SO4; | |||
| Human Class I MHC HLA-A2 in complex with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) p… |
Heteromer P61769; | 93.09 | 2×GOL; 1×NA; 3×FMT; | |||
| TCR F50 recgonizing M1-HLA-A2 |
Heteromer P03485; P61769; | 93.09 | ||||
| Human Class I MHC HLA-A2 in complex with the HuD (G2L,I9V) peptide variant |
Heteromer P61769; | 93.09 | 2×GOL; | |||
| Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2 |
Heteromer P61769; | 93.09 | 3×GOL; | |||
| Human Leukocyte Antigen Class I A02 Carrying LLWNPGMAV |
Heteromer P03314; P61769; | 93.09 | 7×EDO; 1×EPE; 2×PEG; 5×SO4; | |||
| Human Class I MHC HLA-A2 in complex with the decameric Melan-A/MART-1(26-35) peptide |
Heteromer P61769; Q16655; | 93.09 | 2×GOL; 1×NA; | |||
| Peptide length determines the outcome of T cell receptor/peptide-MHCI engagement |
Heteromer P61769; | 93.09 | 18×EDO; 3×GOL; 2×SO4; | |||
| Human Leukocyte Antigen presenting ILGKFLHRL |
Heteromer O14746; P61769; | 93.09 | 15×EDO; 4×GOL; 2×SO4; | |||
| Crystal Structure of ILNAMIVKI peptide bound to HLA-A2 |
Heteromer P61769; | 93.09 | 3×ACT; 4×GOL; 2×MG; | |||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P30305; P61769; | 93.09 | 6×CD; 1×MG; 6×GOL; | |||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P30305; P61769; | 93.09 | 4×GOL; 6×CD; 1×MG; | |||
| Crystal structure of Melanoma Antigen gp100(209-217) Bound to Human Class I MHC HLA-A2 |
Heteromer P40967; P61769; | 93.09 | 9×GOL; | |||
| CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-6V |
Heteromer P61769; | 93.09 | ||||
| Crystal Structure of a citrulline peptide variant of the minor histocompatibility peptide HA-1 in c… |
Heteromer P61769; | 92.73 | ||||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5T peptide variant |
Heteromer P61769; | 92.73 | ||||
| Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1 |
Heteromer P61769; | 93.09 | 5×GOL; | |||
| HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV… |
Heteromer P61769; | 93.09 | ||||
| Crystal structure of Modified Melanoma Antigen gp100(209-T2M) Bound to Human Class I MHC HLA-A2 |
Heteromer P40967; P61769; | 93.09 | 13×GOL; | |||
| Structure of S8 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide |
Heteromer P61769; | 100 | 1×EDO; | |||
| Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-2.1 |
Heteromer P61769; | 93.09 | 2×GOL; | |||
| Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1… |
Heteromer P61769; | 93.04 | 1×ZN; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide V5M v… |
Heteromer P61769; Q03463; | 92.73 | ||||
| Human Leukocyte Antigen A02 presenting ILAKFLHEL |
Heteromer O14746; P61769; | 93.09 | 10×EDO; 1×CA; 2×MES; 3×SO4; 1×GOL; | |||
| Human Class I MHC HLA-A2 in complex with the Tel1p peptide |
Heteromer P38110; P61769; | 93.09 | 5×GOL; | |||
| Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) (R1Y) peptide variant. |
Heteromer P19544; P61769; | 93.09 | 1×GOL; | |||
| Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC Reveal Native Diagonal Bin… |
Heteromer P01848; P61769; P78358; | 93.09 | 8×GOL; 1×MG; 5×SO4; 1×IPA; 1×EPE; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1406-1415 decapeptide |
Heteromer P61769; Q9DIT6; | 92.73 | ||||
| Human Class I MHC HLA-A2 in complex with the native nonameric Melan-A/MART-1(27-35) peptide |
Heteromer P61769; Q16655; | 93.09 | 2×GOL; | |||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; P61769; P78358; | 93.09 | ||||
| Crystal structure of an lmp2a-derived peptide bound to human class i mhc hla-a2 |
Heteromer P13285; P61769; | 93.36 | 5×IOD; 2×EDO; 1×CL; | |||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P61769; | 93.09 | ||||
| A2 HLA complex with L8A heteroclitic variant of Melanoma peptide |
Heteromer P61769; | 93.09 | 11×GOL; 1×MES; | |||
| Human Class I MHC HLA-A2 in complex with the Peptidomimetic ELA-1.1 |
Heteromer P61769; | 93.09 | 6×GOL; | |||
| Rational development of high-affinity T-cell receptor-like antibodies |
Heteromer P61769; P78358; | 93.09 | ||||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5Q peptide variant |
Heteromer P61769; | 92.73 | ||||
| Crystal Structure of the minor histocompatibility peptide HA-1Arg in complex with HLA-A2 |
Heteromer P61769; | 92.73 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide |
Heteromer P61769; | 93.09 | 2×MES; | |||
| Crystal Structure of ILNAMITKI peptide bound to HLA-A2 |
Heteromer P61769; Q68CZ6; | 93.09 | 3×GOL; 1×NA; | |||
| A2 HLA complex with G4A heteroclitic variant of Melanoma peptide |
Heteromer P61769; | 93.09 | 5×GOL; 3×EDO; 4×SO4; | |||
| Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presenta… |
Heteromer P61769; Q9Y4H2; | 93.09 | 5×CD; 1×CO; | |||
| Crystal structure of a complex between the human adenovirus type 2 E3-19K protein and MHC class I m… |
Heteromer P0C213; P61769; P68979; | 93.09 | ||||
| Crystal Structure of the minor histocompatibility peptide HA-1His in complex with HLA-A2 |
Heteromer P61769; Q92619; | 92.73 | ||||
| Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the E63Q and K66A mu… |
Heteromer P14079; P61769; | 92.73 | 13×GOL; 1×SCN; | |||
| HLA Class I antigen |
Heteromer P40967; P61769; | 93.09 | 1×EDO; 2×GOL; | |||
| 1E6 TCR in complex with HLA-A02 carrying RQFGPDWIVA |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P61769; | 93.09 | 15×EDO; 2×PG4; 4×SO4; 1×GOL; | |||
| Human Class I MHC HLA-A2 in complex with the WT-1 (126-134) peptide |
Heteromer P19544; P61769; | 93.09 | 3×GOL; | |||
| Xenoreactive complex AHIII 12.2 TCR bound to p1049/HLA-A2.1 |
Heteromer P01849; P04213; P61769; Q9NPA0; | 93.09 | ||||
| Crystal Structure of HLA-A*0201 in complex with NA231, an influenza epitope |
Heteromer P61769; Q9Q0U7; | 92.73 | ||||
| Human Class I MHC HLA-A2(A150P) in complex with the Tel1p peptide |
Heteromer P38110; P61769; | 92.73 | 2×GOL; | |||
| Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance |
Heteromer P61769; Q9YYH6; | 93.09 | ||||
| HLA-A2.1 KVAELVHFL |
Heteromer E0YFW1; P61769; | 93.09 | ||||
| THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE |
Heteromer P27797; P61769; | 93.09 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide |
Heteromer P61769; | 93.09 | 2×GOL; 1×MES; | |||
| Structure of HLA-A2 P130 |
Heteromer P61769; | 92.73 | 3×PEG; | |||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P61769; | 93.09 | ||||
| HLA Class I antigen |
Heteromer A0A0B4J279; A0A592; A0A5B9; P01848; P40967; P61769; | 93.09 | 10×EDO; 3×GOL; 8×SO4; | |||
| 1E6 TCR in complex with HLA-A02 carrying RQFGPDFPTI |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P61769; | 93.09 | 30×EDO; 3×GOL; 5×SO4; | |||
| A T cell receptor in complex with HLA-A0201 restricted Hepatitis C virus NS3 peptide (KLVALGINAV) |
Heteromer P27958; P61769; | 93.09 | ||||
| Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the K66A mutation in… |
Heteromer P14079; P61769; | 93.09 | 14×GOL; | |||
| Structure of S2-198 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide |
Heteromer P61769; | 100 | 1×TOE; 2×EDO; 1×PO4; | |||
| Crystal structure of LS01-TCR/M1-HLA-A*02 complex |
Heteromer P03485; P61769; | 93.09 | 3×GOL; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant |
Heteromer P61769; Q16655; | 92.73 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 Peptide RT468-476 |
Heteromer P03366; P61769; | 93.09 | 3×MES; 5×GOL; | |||
| Crystal structure of HLA-A0201 in complex with an azobenzene- containing peptide |
Heteromer P61769; | 93.09 | 4×IPA; | |||
| Directed Evolution of Human T-cell Receptor CDR2 residues by phage display dramatically enhances af… |
Heteromer P01848; P61769; P78358; | 93.09 | 1×NA; 4×GOL; | |||
| Human Class I MHC HLA-A2(A150P) in complex with the Tax peptide |
Heteromer P61769; | 92.73 | 1×GOL; | |||
| Crystal structure of non-phosphorylated form of AMPD2 phosphopeptide bound to HLA-A2 |
Heteromer P61769; Q01433; | 93.09 | 3×EDO; 1×NA; | |||
| Human Leukocyte Antigen Class I A02 Carrying LLWNGPMQV |
Heteromer P03314; P61769; | 93.09 | 1×EDO; 1×GOL; 2×PEG; | |||
| A2 HLA complex with E1A heteroclitic variant of Melanoma peptide |
Heteromer P61769; | 93.09 | 6×GOL; 1×SO4; | |||
| 1E6 TCR in complex with HLA-A02 carrying YQFGPDFPIA |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P61769; | 93.09 | 3×SO4; 3×EDO; | |||
| HLA Class I antigen |
Heteromer P40967; P61769; | 93.09 | 1×GOL; 4×EDO; 5×SO4; | |||
| Crystal Structure of ILNAMIAKI peptide bound to HLA-A2 |
Heteromer P61769; Q68CZ6; | 93.09 | 2×GOL; | |||
| Crystal structure of HLA-A2*0201 in complex with a nonameric altered peptide ligand (ALGIGILTV) fro… |
Heteromer P61769; | 93.04 | ||||
| CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX |
Heteromer P61769; | 93.09 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P61769; | 93.09 | ||||
| Crystal structure of a H5-specific CTL epitope variant derived from H5N1 influenza virus in complex… |
Heteromer P61769; Q1WDM0; | 93.09 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer O11822; P61769; | 93.09 | ||||
| Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2… |
Heteromer P09713; P14079; P61769; | 93.09 | ||||
| HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOM… |
Heteromer P43357; P61769; | 93.09 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer O11818; P61769; | 93.09 | ||||
| CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058 |
Heteromer P61769; | 93.09 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P61769; | 93.09 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P61769; | 93.09 | ||||
| CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VA… |
Heteromer P61769; | 93.09 | ||||
| Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, varian… |
Heteromer P61769; | 93.09 | ||||
| Crystal structures of high affinity human T-cell receptors bound to pMHC reveal native diagonal bin… |
Heteromer P01848; P61769; P78358; | 93.09 | 6×SO4; 11×GOL; 1×CA; 1×MG; 1×EPE; | |||
| Newly identified epitope Mn2 from SARS-CoV M protein complexed withHLA-A*0201 |
Heteromer P59596; P61769; | 93.09 | ||||
| STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY … |
Heteromer P04602; P61769; | 97.45 | ||||
| Human Leukocyte Antigen Class I A02 Carrying LLWNGPIAV |
Heteromer P03314; P61769; | 93.09 | 3×GOL; 1×EDO; 6×SO4; 1×PEG; | |||
| Crystal Structure Determination Of HLA A2 Complexed to Peptide GP2 with the substitution (I2L/V5L/L… |
Heteromer P61769; | 93.09 | ||||
| Human Leukocyte Antigen A02 presenting ILAKFLHTL |
Heteromer O14746; P61769; | 93.09 | 1×SO4; 1×EDO; | |||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified TAX (Y5F) peptide |
Heteromer P61769; | 93.09 | 11×GOL; | |||
| Crystal structure of a H5-specific CTL epitope derived from H5N1 influenza virus in complex with HL… |
Heteromer P61769; Q2F4V2; | 93.09 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to HIV-1 envelope peptide env120-128 |
Heteromer P04583; P61769; | 93.09 | 3×MES; 5×GOL; | |||
| Crystal structure of MHC CLass I HLA-A2.1 bound to Cytomegalovirus (CMV) pp65 epitope |
Heteromer P06725; P61769; | 93.09 | 7×GOL; | |||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a Peiodate- cleavable peptide |
Heteromer P06725; P61769; | 93.09 | 2×GOL; 1×MES; | |||
| Crystal structure of non-phosphorylated form of RTF PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with … |
Heteromer O15061; P61769; Q8NHL6; | 93.09 | ||||
| Crystal Structures of High Affinity Human T-Cell Receptors Bound to pMHC RevealNative Diagonal Bind… |
Heteromer P01848; P61769; P78358; | 93.09 | 9×SO4; 3×PGE; 1×7PE; 11×GOL; | |||
| The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its V… |
Heteromer P03485; P61769; | 93.09 | ||||
| Crystal Structure Determination of HLA-A2.1 Complexed to GP2 Peptide Variant(I2L/V5L) |
Heteromer P61769; | 93.09 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a photocleavable peptide |
Heteromer P61769; | 93.09 | 2×GOL; 2×MES; | |||
| The complex between TCR DMF5 and human Class I MHC HLA-A2 with the bound MART-1(27-35) nonameric pe… |
Heteromer P01848; P61769; | 93.09 | ||||
| NYBR1-A2-SLSKILDTV |
Heteromer A0A0B4J277; A0A584; K7N5M3; K7N5M4; P61769; Q9BXX3; | 93.09 | 1×PEG; 2×EDO; 3×GOL; 8×SO4; 1×EPE; | |||
| HLA2.1 KVAELVWFL |
Heteromer E0YFW1; P61769; | 93.09 | ||||
| 1E6 TCR in Complex with HLA-A0e carrying RQWGPDPAAV |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P61769; | 93.09 | 12×EDO; 3×GOL; 4×SO4; | |||
| Structure of S2 TCR in complex with HLA-A*03:01 bound to ELFSYLIEK peptide |
Heteromer P61769; | 100 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to residual fragments of a photocleavable peptide t… |
Heteromer P61769; | 93.09 | 3×GOL; | |||
| A2-MHC Complex carrying FLTGIGIITV |
Heteromer P61769; | 93.09 | 7×EDO; 1×SO4; 1×GOL; | |||
| The complex between high-affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with … |
Heteromer K7N5M3; K7N5M4; P61769; Q16655; | 93.09 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant |
Heteromer P61769; Q16655; | 92.73 | ||||
| Conflicting selective forces affect CD8 T-cell receptor contact sites in an HLA-A2 immunodominant H… |
Heteromer O11822; P61769; | 93.09 | ||||
| Crystal structure of HLA-A2 in complex with LILRB1 |
Heteromer P04585; P61769; Q8NHL6; | 93.09 | ||||
| Crystal structure of DMF5 TCR bound to HLA-A2 presenting synthetic peptide SMLGIGIVPV |
Heteromer P61769; | 93.09 | ||||
| Structures of HLA-A*1101 in complex with immunodominant nonamer and decamer HIV-1 epitopes clearly … |
Heteromer P12499; P61769; | 97.45 | ||||
| POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTE… |
Heteromer P04626; P61769; | 93.09 | ||||
| Large CDR3a loop alteration as a function of MHC mutation |
Heteromer P04213; P61769; Q9NPA0; | 92.73 | ||||
| The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its V… |
Heteromer P61769; | 93.09 | ||||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P61769; Q16655; | 93.09 | 2×EPE; 7×SO4; | |||
| Crystal structure of HLA-A1101 in complex with an azobenzene- containing peptide |
Heteromer P61769; | 97.45 | ||||
| MHC A02 Allele presenting MTSAIGILVP |
Heteromer P61769; | 93.09 | ||||
| 1E6 TCR in complex with HLA-A02 carrying MVW peptide |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P61769; | 93.09 | 5×EDO; 5×SO4; 1×GOL; | |||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P61769; | 93.09 | 1×TAM; 11×SO4; | |||
| Crystal structure of LS10-TCR/M1-HLA-A*02 complex |
Heteromer P03485; P61769; | 93.09 | 1×EDT; | |||
| HLA class I histocompatibility antigen |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01848; P61769; | 93.09 | 4×SO4; | |||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P03485; P61769; | 93.09 | ||||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P14079; P61769; | 93.09 | ||||
| Human Leukocyte Antigen Class I A02 Carrying LLWAGPMAV |
Heteromer P03314; P61769; | 93.09 | 1×NA; 2×EDO; 5×SO4; 2×GOL; | |||
| CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX |
Heteromer P61769; Q9NPA0; | 93.09 | ||||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P04588; P61769; | 93.09 | ||||
| COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201 |
Heteromer A0A0K0K1A5; A0A5B9; P01848; P04437; P14079; P61769; | 93.09 | ||||
| AH3 recognition of mutant HLA-A2 W167A |
Heteromer P01849; P61769; Q9NPA0; | 92.73 | ||||
| The Structural Dynamics and Energetics of an Immunodominant T-cell Receptor are Programmed by its V… |
Heteromer P61769; | 93.09 | ||||
| Crystal structure of the T-cell receptor NYE_S1 bound to HLA A2*01-SLLMWITQV |
Heteromer P61769; P78358; | 92.96 | ||||
| RD-1 Mart-1 High bound to Mart-1 decameric peptide (ELA) in complex with HLA-A2 |
Heteromer A0A075B6T6; A0A0K0K1A5; P61769; Q16655; | 92.86 | ||||
| Crystal structure of MHC CLass I HLA-A2.1 bound to a peptide representing the epitope of the H5N1 (… |
Heteromer P61769; Q33CG5; | 93.09 | 1×GOL; 1×MES; | |||
| The complex between high affinity TCR DMF5(alpha-D26Y,beta-L98W) and human Class I MHC HLA-A2 with … |
Heteromer P61769; Q16655; | 93.09 | ||||
| Crystal structure of the T-cell receptor NYE_S2 bound to HLA A2*01-SLLMWITQV |
Heteromer P61769; P78358; | 93.09 | ||||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5K-4-[3-Indo… |
Heteromer P01848; P01850; P61769; | 93.09 | 5×SO4; 13×GOL; 1×3IB; | |||
| The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(27-35) nonameric pe… |
Heteromer P01848; P61769; Q16655; | 93.09 | ||||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P04582; P61769; | 93.09 | ||||
| 1E6-A*0201-ALWGPDPAAA Complex, Triclinic |
Heteromer P01308; P61769; | 93.09 | ||||
| Structure of HLA-A2 in complex with D76N b2m mutant and NY-ESO1 double mutant |
Heteromer P61769; | 93.09 | 3×CL; 1×GOL; | |||
| COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8 |
Heteromer P01732; P61769; | 93.09 | ||||
| The complex between TCR DMF5 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) peptide |
Heteromer P01848; P61769; | 93.09 | ||||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the bound HuD peptide |
Heteromer P01848; P61769; | 93.09 | 7×GOL; 1×SO4; | |||
| Human Leukocyte Antigen Class I A02 Carrying LLWNGPMHV |
Heteromer P03314; P61769; | 93.09 | 2×PEG; 3×SO4; 1×GOL; | |||
| Crystal structure of non-phosphorylated form of RQA_V phosphopeptide bound to HLA-A2 in complex wit… |
Heteromer P33241; P61769; Q8NHL6; | 93.09 | 1×EDO; | |||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the bound Tel1p peptide |
Heteromer P38110; P61769; | 93.09 | 6×GOL; | |||
| an affinity enhanced T cell receptor in complex with HLA-A0201 restricted HCV NS3 peptide KLVALGINAV |
Heteromer P27958; P61769; | 93.09 | ||||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P61769; | 93.09 | 4×SO4; 2×GOL; | |||
| Human Leukocyte Antigen A02 presenting ILGKFLHWL |
Heteromer O14746; P61769; | 93.09 | 6×EDO; 1×SO4; | |||
| 1E6-A*0201-ALWGPDPAAA Complex, Monoclinic |
Heteromer P01308; P61769; | 93.09 | 2×SO4; | |||
| The complex between the high affinity version of A6 TCR (A6c134) and human Class I MHC HLA-A2 with … |
Heteromer P0C213; P61769; | 93.09 | 10×GOL; | |||
| TCR-peptide specificity overrides affinity enhancing TCR-MHC interactions |
Heteromer H2RG00; K7N5N2; O14746; P01850; P61769; | 93.09 | 1×GOL; 2×EDO; | |||
| 868 TCR in complex with HLA A02 presenting SLYFNTIAVL |
Heteromer P04591; P61769; | 93.09 | 13×EDO; 3×GOL; 2×SO4; | |||
| Structure of 5F3 TCR in complex with HLA-A2/MART-1 |
Heteromer P61769; Q6PJ56; | 93.09 | 1×NAG; | |||
| A2-MHC Complex carrying FATGIGIITV |
Heteromer P61769; | 93.09 | 4×SO4; | |||
| Crystal Structure of HLA-A*2402 Complexed with a telomerase peptide |
Heteromer O14746; P61769; | 91.64 | 5×SO4; 2×GOL; | |||
| Newly identified epitope from SARS-CoV membrane protein complexed with HLA-A*0201 |
Heteromer P59596; P61769; | 93.04 | ||||
| The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) decame… |
Heteromer P01848; P61769; Q16655; | 93.09 | ||||
| Crystal structure of human class i mhc (hla-a2.1) complexed with beta 2-microglobulin and hiv-rt va… |
Heteromer P61769; | 93.09 | ||||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(3,4-difluo… |
Heteromer P01850; P61769; | 93.09 | 6×GOL; | |||
| CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V |
Heteromer P61769; | 93.09 | ||||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(4-fluoroPh… |
Heteromer P01848; P01850; P61769; | 93.09 | 4×GOL; | |||
| HLA class I histocompatibility antigen |
Heteromer P61769; | 93.09 | 2×EPE; 4×SO4; 2×EDO; | |||
| Human Leukocyte Antigen A02 presenting ILAKFLHWL, in complex with cognate T-Cell Receptor |
Heteromer A0A0B4J277; A0A0K0K1A5; K7N5M3; K7N5M4; O14746; P61769; | 93.09 | 5×EDO; 1×GOL; 5×SO4; | |||
| Large CDR3a loop alteration as a function of MHC mutation. |
Heteromer P01849; P04213; P61769; Q9NPA0; | 93.09 | ||||
| 868 TCR in complex with HLA A02 presenting SLYNTIATL |
Heteromer P04591; P61769; | 93.09 | 5×EDO; 2×GOL; 8×SO4; | |||
| Rational development of high-affinity T-cell receptor-like antibodies |
Heteromer P61769; P78358; | 93.09 | ||||
| CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUT… |
Heteromer P61769; | 92.94 | ||||
| MHC A02 Allele presenting MTSAIGILPV |
Heteromer P61769; | 93.09 | ||||
| 868 TCR in complex with HLA A02 presenting SLYNTVATL |
Heteromer P04591; P61769; | 93.09 | 4×EDO; 3×SO4; | |||
| Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-G4E |
Heteromer A0A075B6N1; A0A087WT01; A0A5B9; P01848; P61769; | 93.09 | ||||
| The complex between TCR a7b2 and human Class I MHC HLA-A0201-WT1 with the bound RMFPNAPYL peptide. |
Heteromer P19544; P61769; | 93.09 | 2×EDO; | |||
| The complex among DMF5(alpha-D26Y, alpha-Y50A,beta-L98W) TCR, human Class I MHC HLA-A2 and MART-1(2… |
Heteromer A0A075B6T6; A0A1B0GXE1; K7N5M4; P01848; P61769; Q16655; | 93.09 | ||||
| THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEP… |
Heteromer P12901; P61769; | 93.09 | ||||
| Structural basis for ineffective T-cell responses to MHC anchor residue improved heteroclitic pepti… |
Heteromer P61769; Q16655; | 93.09 | 4×EDO; | |||
| Structure of ESK1 in complex with HLA-A*0201/WT1 |
Heteromer P19544; P61769; | 93.09 | ||||
| 1E6 TCR in Complex with HLA-A02 carrying AQWGPDPAAA |
Heteromer A0A0B4J271; A0A0B4J2E0; A0A5B9; P01308; P01848; P61769; | 93.09 | ||||
| Structure of wtMHC class I with NY-ESO1 double mutant |
Heteromer P61769; | 93.09 | 2×CL; 1×GOL; | |||
| Crystal structure of the T-cell receptor NYE_S3 bound to HLA A2*01-SLLMWITQV |
Heteromer P61769; P78358; | 93.09 | ||||
| HLA class I histocompatibility antigen |
Heteromer P61769; | 93.09 | 4×SO4; | |||
| human 199.54-16 TCR in complex with Melan-A/MART-1 (26-35) peptide and HLA-A2 |
Heteromer A0A075B6T6; A0A0C4ZKA8; A0A5B3; K7N5N2; P61769; Q16655; | 92.73 | 1×SCN; 2×K; 1×CL; | |||
| Crystal structure of non-phosphorylated form of RLS PHOSPHOPEPTIDE BOUND TO HLA-A2 in complex with … |
Heteromer P61769; Q8NC44; Q8NHL6; | 93.09 | ||||
| human 199.16 TCR in complex with Melan-A/MART-1 (26-35) peptide and HLA-A2 |
Heteromer A0A075B6N1; P01848; P61769; Q16655; | 92.73 | 1×NA; | |||
| HLA-A2 (A*02:01) bound to a peptide from the Epstein-Barr virus BRLF1 protein |
Heteromer P61769; Q3KSS7; | 93.09 | ||||
| Neoantigen p53R175H-specific TCR 6-11 binds to p53R175H-HLA-A2 |
Heteromer P04637; P61769; | 93.09 | ||||
| Crystal Structure of HLA-A2 Bound to LIR-1, a Host and Viral MHC Receptor |
Heteromer P12499; P61769; Q8NHL6; | 93.09 | ||||
| Structure of a fully assembled T-cell receptor engaging a tumor-associated peptide-MHC I |
Heteromer P04234; P07766; P09693; P20963; P40967; P61769; | 93.09 | 6×NAG; | |||
| Structure of the P1B7 antibody bound to the Sotorasib-modified KRas G12C peptide presented by the A… |
Heteromer P01116; P61769; | 100 | 1×MOV; | |||
| Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjuga… |
Heteromer P01116; P61769; | 100 | 1×MOV; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with EBV bmlf1-280-288 nonapeptide |
Heteromer P61769; Q3KSU1; | 92.7 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide |
Heteromer P61769; Q03463; | 92.7 | 1×CIT; | |||
| Crystal structure of HA-1 minor histocompatibility antigen bound to human class I MHC HLA-A2 |
Heteromer P61769; Q92619; | 93.07 | ||||
| Crystal structure of BRLF peptide from EBV in complex with HLA-A1101. |
Heteromer P61769; | 97.44 | 7×GOL; | |||
| The structure of HLA-A*3003/NP44 |
Heteromer P61769; Q9Q0U8; | 95.98 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with AFP137 nonapeptide |
Heteromer P02771; P61769; | 92.7 | ||||
| Crystal Structure of HLA-A*0201 in complex with FLNDK, a 15 mer self-peptide |
Heteromer P61769; | 93.07 | 2×PEG; 1×CL; | |||
| Structure of HLA-A2:01 with the 12-mer peptide F12K |
Heteromer B6KDY1; P61769; | 93.07 | 1×GOL; | |||
| The structure of HLA-A*3001/RT313 |
Heteromer P04585; P61769; | 96.72 | ||||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV peptide |
Heteromer P06725; P61769; | 92.7 | ||||
| Crystal Structure of PKD2 Phosphopeptide Bound to Human Class I MHC HLA-A2 |
Heteromer P61769; Q9BZL6; | 93.07 | 4×EDO; | |||
| HLA-A*1101 in complex with HBV peptide homologue |
Heteromer P61769; | 97.44 | 3×SO4; | |||
| The structure of HLA-A*3003/MTB |
Heteromer P61769; P9WNK3; | 95.98 | ||||
| Crystal Structure of RQA_M Phosphopeptide Bound to HUMAN Class I MHC HLA-A2 |
Heteromer P33241; P61769; | 93.07 | 2×EDO; | |||
| HLA-A24 in complex with HIV-1 Nef126-10(8I10F) |
Heteromer P04603; P61769; | 91.61 | ||||
| Crystal structure of peptide in complex with HLA-A1101. |
Heteromer P61769; | 97.44 | 4×GOL; | |||
| Crystal Structure of HLA-A*0201 in complex with ALQDA, a 15 mer self-peptide |
Heteromer P61769; | 93.07 | 4×CL; 3×PEG; 2×MG; | |||
| Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PB1 (498-5… |
Heteromer P61769; Q9YXL6; | 91.61 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide V6G v… |
Heteromer P06725; P61769; | 92.7 | ||||
| Crystal structure of AMPD2 phosphopeptide bound to HLA-A2 |
Heteromer P61769; Q01433; | 93.07 | 4×EDO; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide V6C v… |
Heteromer P06725; P61769; | 92.7 | ||||
| The High Resolution Crystal Structure of HLA-A1 Complexed with the MAGE-A1 Peptide |
Heteromer P43355; P61769; | 94.53 | 3×GOL; | |||
| Crystal structure of 10-mer peptide from EBV in complex with HLA-A1101. |
Heteromer P13285; P61769; | 97.44 | 2×GOL; | |||
| The complex between H27-14 TCR and HLA-A24 bound to HIV-1 Nef134-10(6L) peptide |
Heteromer P61769; Q9WPU2; | 91.61 | ||||
| Structure of HLA-A68 complexed with a tumor antigen derived peptide |
Heteromer P40126; P61769; | 92.34 | 1×GOL; | |||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-T8A peptide variant |
Heteromer P61769; | 92.7 | ||||
| Structure of HLA-A2:01 with peptide G9L |
Heteromer P61769; | 93.07 | 3×GOL; | |||
| Structure of HLA-A2:01 with the 11-mer peptide F11V |
Heteromer P61769; S7UWA0; | 93.07 | 1×GOL; | |||
| Crystal Structure of HLA-A*68:01 in complex with NP145-156, a 12 mer influenza peptide |
Heteromer P61769; Q9Q0U8; | 94.16 | 1×IOD; 3×MG; 2×SO4; | |||
| Crystal structure of non-phosphorylated form of PKD2 phosphopeptide bound to HLA-A2 |
Heteromer P61769; Q9BZL6; | 93.07 | 3×CD; 2×GOL; | |||
| Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009H1N1 PB1 (496-50… |
Heteromer P61769; Q9YXL6; | 91.61 | ||||
| Crystal Structure of HLA-A*0201 in complex with M1-G4E |
Heteromer P61769; | 92.7 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCMV pp65-495-503 nonapeptide M5A v… |
Heteromer P61769; Q6SW59; | 92.7 | ||||
| Crystal structure of dual peptide from EBV in complex with HLA-A*11:01 |
Heteromer P13285; P61769; | 97.44 | 4×GOL; | |||
| HLA-A24 in complex with HIV-1 Nef134-10(wt) |
Heteromer P61769; Q9YYU8; | 91.61 | ||||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5V peptide variant |
Heteromer P61769; | 92.7 | ||||
| Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P42336; P61769; | 100 | 5×GOL; 3×FMT; | |||
| Crystal Structure of HLA A*0101 in complex with NP44-S7N, an 9-mer influenza epitope |
Heteromer P61769; Q07FI1; | 94.53 | ||||
| HLA-A24 in complex with HIV-1 Nef126-10(8T10F) |
Heteromer P61769; Q77378; | 91.61 | ||||
| Newly identified epitope V60 from HBV core protein complexed with HLA-A*0201 |
Heteromer P61769; Q9QAC5; | 93.07 | ||||
| Crystal structure of RQA_V phosphopeptide bound to HLA-A2 |
Heteromer P33241; P61769; | 93.07 | 3×EDO; 1×NA; | |||
| HIV RT derived peptide complexed to HLA-A*0301 |
Heteromer P61769; Q9YV12; | 100 | ||||
| Crystal Structure of HLA-A*0201 in complex with M1-F5L |
Heteromer P61769; | 92.7 | ||||
| Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide |
Heteromer P42336; P61769; | 100 | 2×GOL; | |||
| HLA*A2402 complexed with HIV nef138 Y2F mutant 10mer epitope |
Heteromer P04601; P61769; | 91.61 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide G4M-V… |
Heteromer P61769; Q03463; | 92.7 | ||||
| Crystal Structure of HLA-A*0201 in complex with M1-L3W |
Heteromer P61769; | 92.7 | ||||
| PF6-M1-HLA-A2 |
Heteromer P03485; P61769; | 93.07 | ||||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-T8V peptide variant |
Heteromer P61769; | 92.7 | ||||
| Crystal structure of PKD2 phosphopeptide bound to HLA-A2 |
Heteromer P61769; Q9BZL6; | 93.07 | 4×CD; 1×GOL; | |||
| Crystal structure of human 0606T1-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P42336; P61769; | 100.0 | 13×GOL; | |||
| Crystal structure of the binary complex between HLA-A2 and HCMV NLV-M5S peptide variant |
Heteromer P61769; | 92.7 | ||||
| Crystal structure of HLA-A1:MAGE-A1 in complex with Fab-Hyb3 |
Heteromer P43355; P61769; | 94.53 | 2×GOL; | |||
| HLA*A2402 complex with HIV nef138 Y2F-8mer mutant epitope |
Heteromer P04601; P61769; | 91.61 | ||||
| Crystal Structure of KMD Phosphopeptide Bound to Human Class I MHC HLA-A2 |
Heteromer P61769; Q86UW6; | 93.07 | 1×EDO; | |||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with Melan-A MART1 decapeptide variant |
Heteromer P61769; Q16655; | 92.7 | ||||
| Crystal Structure Analysis of NY-ESO-1 epitope, SLLMWITQC, in complex with HLA-A2 |
Heteromer P61769; P78358; | 93.07 | 1×SO4; | |||
| Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25… |
Heteromer A0A0X9JHC1; P61769; | 91.61 | ||||
| Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25… |
Heteromer A0A0X9JHC1; P61769; | 91.61 | ||||
| HLA-A24 in complex with HIV-1 Nef134-8(2F) |
Heteromer P04601; P61769; | 91.61 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS4b-1807-1816 decapeptide |
Heteromer P61769; Q9DIT6; | 92.7 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with EBV bmlf1-280-288 nonapeptide T4P v… |
Heteromer P61769; Q3KSU1; | 92.7 | ||||
| Crystal structure of LMP2 peptide from EBV in complex with HLA-A*11:01 |
Heteromer P13285; P61769; | 97.44 | 5×GOL; | |||
| Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQS, in complex with HLA-A2 |
Heteromer P61769; | 93.07 | 1×SO4; | |||
| HIV Nef derived peptide Nef73 complexed to HLA-A*0301 |
Heteromer P04601; P61769; | 100 | ||||
| Crystal Structure of HLA A*0101 in complex with NP44, an 9-mer influenza epitope |
Heteromer P03466; P61769; | 94.53 | ||||
| Recognition of peptide-MHC by a V-delta/V-beta TCR |
Heteromer P61769; Q9YYU8; | 91.61 | ||||
| HLA*A2402 complexed with HIV nef138 10mer epitope |
Heteromer P04601; P61769; | 91.61 | ||||
| Structure of HLA-A68 complexed with an HIV derived peptide |
Heteromer P61769; Q9YXY3; | 94.16 | ||||
| MAGE-A3 Reactive TCR in complex with Titin Epitope in HLA-A1 |
Heteromer A0A0B4J279; A0A578; A0A5B9; P01848; P61769; Q8WZ42; | 94.53 | 1×GOL; 11×SO4; | |||
| HLA*A2402 complexed with HIV nef138 8mer epitope |
Heteromer P04601; P61769; | 91.61 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide N3S v… |
Heteromer P61769; Q03463; | 92.7 | ||||
| Newly identified epitope N1 derived from SARS-CoV N protein complexed with HLA-A*2402 |
Heteromer P59595; P61769; | 91.61 | ||||
| HLA-A24 in complex with HIV-1 Nef134-8(wt) |
Heteromer P04601; P61769; | 91.61 | ||||
| Crystal Structure of HLA-A*2402 Complexed with a Newly Identified Peptide from 2009 H1N1 PA (649-65… |
Heteromer P61769; Q9YXL3; | 91.61 | ||||
| The complex between H27-14 TCR and HLA-A24 bound to HIV-1 Nef134-10(wt) peptide |
Heteromer P61769; Q9YYU8; | 91.61 | ||||
| Crystal Structure of HLA-A*1101 in complex with H1-22, an influenza A(H1N1) virus epitope |
Heteromer P61769; P68043; | 97.44 | ||||
| Crystal Structure of MHC class I HLA-A2 molecule complexed with HCV NS3-1073-1081 nonapeptide C6V v… |
Heteromer P61769; Q03463; | 92.7 | ||||
| Human Class I MHC HLA-A2 in complex with synthetic peptide MMWDRGLGMM |
Heteromer P61769; | 93.07 | ||||
| HLA-A24 in complex with HIV-1 Nef134-10(6L) |
Heteromer P61769; Q9WPU2; | 91.61 | ||||
| Crystal structure of killer cell immunoglobulin-like receptor KIR2DS2 in complex with HLA-A |
Heteromer P43631; P61769; Q76ZQ3; | 97.44 | ||||
| Engineered Human HLA_A2 MHC Class I molecule in complex with TCR and SV9 peptide |
Heteromer A0A0B4J279; A0A0K0K1A5; K7N5M4; K7N5N2; P61769; | 92.34 | 1×GOL; 1×ACT; | |||
| The complex between C1-28 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide |
Heteromer P61769; Q9YYU3; | 91.61 | 3×CO; | |||
| Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQA, in complex with HLA-A2 |
Heteromer P61769; | 93.07 | 1×SO4; | |||
| Structure of HLA-A2:01 with peptide Y9L |
Heteromer P61769; | 93.07 | 3×GOL; | |||
| Crystal Structure of HLA-A*1101 in complex with H7-22, an influenza A(H7N9) virus epitope |
Heteromer P61769; Q9Q0U8; | 97.44 | ||||
| Crystal structure of a MHC class I-peptide complex |
Heteromer P60201; P61769; | 100 | ||||
| COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201 |
Heteromer A0A075B6T6; A0A0K0K1A5; A0A5B9; P01848; P14079; P61769; | 93.07 | 2×EMC; | |||
| The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide in space group P2121… |
Heteromer P61769; Q9YYU3; | 91.61 | ||||
| HLA-A24 in complex with HIV-1 Nef134-10(2F) |
Heteromer P61769; Q9YYU3; | 91.61 | ||||
| MAGE-A3 reactive TCR in complex with MAGE-A3 in HLA-A1 |
Heteromer A0A0B4J279; A0A578; A0A5B9; P01848; P43357; P61769; | 94.53 | 7×SO4; | |||
| Crystal structure of peptide-HLA-A24 bound to S19-2 V-delta/V-beta TCR |
Heteromer P03407; P61769; | 91.61 | ||||
| Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances af… |
Heteromer P01848; P01850; P61769; P78358; | 93.07 | ||||
| Structure of HLA-A2:01 with peptide Y10L |
Heteromer P61769; | 93.07 | 1×GOL; | |||
| The complex between T36-5 TCR and HLA-A24 bound to HIV-1 Nef134-10(2F) peptide |
Heteromer P61769; Q9YYU3; | 91.61 | ||||
| Crystal Structure of HLA-A*2402 in complex with 2009 pandemic influenza A(H1N1) virus and avian inf… |
Heteromer A0A0X9JHC1; P61769; | 91.61 | ||||
| Plasticity of human CD8 binding to peptide-HLA-A*2402 |
Heteromer P01732; P61769; Q9YYU8; | 91.61 | ||||
| Structure of HLA-A68 complexed with an HIV Env derived peptide |
Heteromer P61769; Q70626; | 92.34 | ||||
| CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A |
Heteromer P01848; P61769; | 93.07 | ||||
| Crystal structure of the public RA14 TCR in complex with the HCMV dominant NLV/HLA-A2 epitope |
Heteromer P01848; P61769; | 92.7 | 1×SO4; 1×CL; | |||
| STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R |
Heteromer P61769; | 93.07 | ||||
| STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A |
Heteromer P01848; P61769; | 92.7 | ||||
| Crystal Structure of HLA-A*11:01-GTS3 |
Heteromer P61769; Q6YMS4; | 97.44 | 1×K; | |||
| The complex between TCR JKF6 and human Class I MHC HLA-A2 presenting the MART-1(27-35)(A27L) peptide |
Heteromer P61769; Q16655; | 92.83 | ||||
| D30 TCR in complex with HLA-A*11:01-GTS1 |
Heteromer A0A087WSZ9; K7N5N2; P17763; P61769; | 97.44 | ||||
| Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the… |
Heteromer P61769; Q9UM73; | 94.53 | ||||
| Crystal structure of human 21LT2-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide |
Heteromer P42336; P61769; | 100 | 1×ACT; 1×GOL; | |||
| Crystal Structure of HLA-A*11:01 with GTS1 peptide |
Heteromer P17763; P61769; | 97.44 | 1×CL; | |||
| Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25… |
Heteromer A0A0X9JHC1; P61769; | 91.61 | ||||
| D30 TCR in complex with HLA-A*11:01-GTS3 |
Heteromer A0A087WSZ9; K7N5N2; P61769; Q6YMS4; | 97.44 | ||||
| Crystal Structure of HLA-A*2402 in complex with avian influenza A(H7N9) virus-derived peptide H7-25… |
Heteromer A0A0X9JHC1; P61769; | 91.61 | ||||
| G12V-TCR complex with HLA-A3 |
Heteromer P01116; P61769; | 100 | ||||
| Crystal structure of TCR C7 in complex with HCMV NLV epitope presented by HLA-A2 |
Heteromer P18139; P61769; | 93.07 | ||||
| Crystal structure of TCR PF8 in complex with flu MP(58-66) epitope presented by HLA-A2 |
Heteromer K7N5M3; P03485; P61769; | 93.1 | ||||
| HLA-A*01:01 complex with NRAS Q61K peptide by NMR |
Heteromer P01111; P61769; | 94.53 | ||||
| Structure of the human MHC I peptide-loading complex editing module |
Heteromer O15533; P27797; P30101; P61769; | 100 | 1×NAG; 1×NAG; | |||
| Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjuga… |
Heteromer P01116; P61769; | 100 | 1×MOV; | |||
| Structure of the human PLC editing module |
Heteromer O15533; P27797; P30101; P61769; | 100 | 1×NAG; 1×MAN; | |||
| Structure of HLA-A2:01 with peptide G9V |
Heteromer P61769; | 93.04 | 3×GOL; | |||
| Crystal structure of C25-NLV-HLA-A2 complex |
Heteromer P18139; P61769; | 93.04 | 1×IMD; | |||
| Structure of HLA-A2:01 with peptide G13E |
Heteromer P61769; | 93.04 | ||||
| Crystal structure of DMF5 TCR bound to HLA-A2 presenting synthetic peptide MMWDRGLGMM |
Heteromer P61769; | 92.94 | ||||
| Structure of HLA-A2:01 with peptide G11N |
Heteromer P61769; | 93.04 | 2×GOL; | |||
| Structure of HLA-A2:01 with peptide Y16R |
Heteromer P61769; | 93.04 | 2×GOL; 1×NA; | |||
| Crystal structure of 1406 TCR bound to HLA-A2 with HCV 1406-1415 antigen peptide |
Heteromer P27958; P61769; | 92.69 | ||||
| The complex between TIL 1383i TCR and human Class I MHC HLA-A2 with the bound Tyrosinase(369-377)(N… |
Heteromer P14679; P61769; | 93.7 | ||||
| Crystal structure of a complex between the Human adenovirus type 4 E3-19K protein and MHC class mol… |
Heteromer P14079; P61769; Q8BEL5; | 92.8 | ||||
| DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE |
Heteromer P61769; | 94.07 | 1×ALA; 1×ARG; | |||
| HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1 |
Heteromer P61769; | 92.96 | ||||
| SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68 |
Heteromer P61769; | 94.07 | ||||
| STRUCTURE OF THE HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN, HLA-A2 |
Heteromer P61769; | 92.96 | ||||
| Crystal Structure of the JM22 TCR in complex with HLA-A*0201 in complex with M1-F5L |
Heteromer A0A075B6N1; A0A087WT01; A0A5B9; P01848; P61769; | 92.45 | ||||
| THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE … |
Heteromer P61769; | 94.29 | ||||
| HIV-1 Nef in complex with MHC-I cytoplasmic domain and Mu1 adaptin subunit of AP1 adaptor (second d… |
Heteromer P35585; Q90VU7; | 89.47 | ||||
| AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated wide membrane tubes, centered on beta-Arf1 |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 18×GTP; 18×MG; | |||
| AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated narrow membrane tubes, centered on beta-A… |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 12×GTP; 12×MG; | |||
| Asymmetric unit of AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated wide(r) membrane tubes |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 3×GTP; 3×MG; | |||
| AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated wide membrane tubes, centered on gamma-Ar… |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 18×GTP; 18×MG; | |||
| beta-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide … |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 6×GTP; 6×MG; | |||
| Asymmetric unit of AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated narrow membrane tubes |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 2×GTP; 2×MG; | |||
| gamma-Arf1 homodimeric interface within AP-1, Arf1, Nef lattice on narrow membrane tubes |
Heteromer A0A8C2UGL4; P22892; P35585; Q10567; Q90VU7; Q96PC3; | 83.33 | 4×GTP; 4×MG; | |||
| gamma-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide… |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 6×GTP; 6×MG; | |||
| beta-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide … |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 4×GTP; 4×MG; | |||
| AP-1, Arf1, Nef lattice on MHC-I lipopeptide incorporated narrow membrane tubes, centered on gamma-… |
Heteromer A0A8C2UGL4; P22892; P35585; Q10567; Q90VU7; Q96PC3; | 83.33 | 12×GTP; 12×MG; | |||
| beta-Arf1 homodimeric interface within AP-1, Arf1, Nef, MHC-I lattice on narrow tubes |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 2×MG; 2×GTP; | |||
| gamma-Arf1 mediated dimeric assembly of AP-1, Arf1, Nef complex within lattice on MHC-I lipopeptide… |
Heteromer P22892; P35585; P84077; Q10567; Q90VU7; Q96PC3; | 83.33 | 4×GTP; 4×MG; | |||
| Structure of HLA-DR1 with a bound peptide with non-optimal alanine in the P1 pocket |
Heteromer P01903; P01911; | 71.43 | ||||
| HLA-DR1 (DRA, DRB1 0101) HUMAN CLASS II HISTOCOMPATIBILITY PROTEIN (EXTRACELLULAR DOMAIN) COMPLEXED… |
Heteromer P01903; P01911; | 78.57 | ||||
| HIV-1 Nef in complex with MHC-I cytoplasmic domain and Mu1 adaptin subunit of AP1 adaptor (second d… |
Heteromer P35585; Q90VU7; | 83.33 | ||||
| Structure of the HLA-E-VMAPRTLVL/GF4 TCR complex |
Heteromer P13747; P61769; | 88.89 | ||||
| HLA-A*0201 single chain trimer with HPV.16 E7 peptide LLMGTLGIV | monomer | 92.62 | ||||
| HLA-A*0201 single chain trimer with murine H2K alpha 3 domain and HPV.16 E7 peptide YMLDLQPET | monomer | 93.75 | ||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7u1r.1.A | monomer | 0.84 | 93.70 | |||
1 SWISS-MODEL model built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 7tlt.1.A | monomer | 0.85 | 92.60 | |||